Life Sciences Data Platform for Pharma, Biotech and Investors
Pipeline, trials, KOLs, regulatory and catalysts in one platform. 84K+ assets · 480K trials · refreshed nightly.
Start 1 month free trial
No credit card required
GxP-friendly
Cancel anytime
Search by
Company
84K+
Assets in Pipeline
480K
Clinical Trials
↑ Live feed
481,234
Active Studies
320K
Investigators
62K
KOL Profiles
190
Countries
Built for Life Sciences Teams
Every R&D and commercial function, one platform
From CI to BD — designed for teams that develop, license, and commercialize therapeutics.
Competitive Intel
Track competitor pipelines, MoA overlap, and trial readouts.
Clinical Operations
Site selection, investigator identification, and enrollment forecasting.
Regulatory Affairs
FDA, EMA, PMDA filings, designations, and approval tracking.
Medical Affairs
KOL mapping, publications, congress activity, and engagement.
Commercial Strategy
Market sizing, payer landscape, and launch planning.
BD & Licensing
Source assets by stage, MoA, and indication for in-licensing.
Investor Relations
Catalyst calendars, peer benchmarking, and analyst insights.
VC & Crossover
Source biotech deals by platform, KOL, and pre-clinical signal.
Assets in Pipeline
Pre-clinical → marketed
84K+
Across all therapeutic areas and modalities
+480 new assets last 30 days
Clinical Trials
Active + completed
481,234
Active studies tracked across global registries
Nightly registry refresh
Investigator Database
Global PI network
320K
Active investigators with trial history + KOL score
62K full KOL profiles
Catalysts Tracked
Readouts + PDUFA
~2.4K
Upcoming readouts, FDA decisions, AdComs
Webhooks on every catalyst
Life Sciences Problems We Solve
Eight R&D and commercial scenarios
01Map Competitor PipelinesPre-clinical → Phase 3 → approved · all indicationsPipeline
02Find Trial InvestigatorsBy indication, MoA, prior trial volumeSites
03Track FDA ApprovalsPDUFA dates, designations, AdCom outcomesReg
04Identify KOLs by TAScore by publications, trials, congress, NIH grantsKOL
05Forecast Trial EnrollmentSite activation curves and enrollment velocityForecast
06Source Licensing AssetsPre-clinical and Phase 1 assets by MoABD
07Monitor CatalystsTrial readouts, FDA decisions, congress datesCalendar
08Analyse Payer LandscapeCoverage policies, prior auth, formulary tierAccess
Life Sciences Data Types
11 intelligence layers per asset
Drug Pipeline DB84K+ assets · pre-clinical → marketedCore
Clinical Trial RegistryClinicalTrials.gov + EU + JP + global · 480K trialsTrials
FDA / EMA FilingsNDAs, BLAs, INDs, AdCom outcomesReg
Investigator Database320K+ active PIs with trial historyPI
KOL Influence ScorePublication, citation, trial, congress signalKOL
Publications & CongressPubMed + ASCO/ASH/AHA abstractsResearch
Patent LandscapeComposition + method + formulation patentsIP
Payer & AccessFormulary, prior auth, coverage decisionsAccess
Mechanism MappingMoA, target, modality, pathway curatedScience
Catalyst CalendarReadouts, PDUFA, AdCom, congressCalendar
Geo & Site NetworkTrial sites by country, region, network affiliationGeo
Asset 360 Dashboard
Every signal, one asset
Mechanism, trials, investigators, regulatory, IP, catalyst calendar, and timeline of milestones.
Asset Profile — MXY-2240 (anti-PD-1)
Oncology · NSCLC · Phase 3
MechanismAnti-PD-1 mAb
Indication1L NSCLC · TPS ≥50%
StagePhase 3 — pivotal
FDA DesignationBreakthrough Therapy
Estimated ReadoutQ3 2026
Composition PatentExpires 2034
Competing Assets in MoA
Pivoted via mechanism + indication
1Tirzepatide (Eli Lilly) — Phase 3 readoutScore 96
2Retatrutide (Eli Lilly) — Phase 2Score 88
3CagriSema (Novo Nordisk) — Phase 3Score 82
4Orforglipron (Lilly) — Phase 3 oralScore 74
Timeline
Recent program milestones
8d agoLast patient enrolled in pivotal trial
2mo agoFDA Breakthrough Therapy designation granted
4mo agoESMO presentation — Phase 2 ORR 48%
Use Cases
Built for real R&D workflows
Eight proven use cases — from CI to commercial launch.
R&D & Clinical
Discover, develop, deliver
01Pipeline MappingTrack competitor assets by MoA + indication
02Trial Site SelectionPick sites by investigator + enrollment history
03Regulatory TrackingFDA, EMA, PMDA filings and decisions
04Catalyst MonitoringReadouts, AdComs, congress presentations
Commercial & BD
License, launch, expand
05BD Asset SourcingFind pre-clinical assets by MoA + IP
06KOL EngagementRank by influence, congress, NIH grants
07Launch PlanningPayer landscape + market sizing per TA
08Investor DiligencePipeline benchmarking + catalyst calendar
Life Sciences Graphs
R&D trends, visualised
FDA approval cadence, pipeline phase distribution, and new trial registrations.
FDA Novel Approvals
Monthly NME + BLA approvals — last 12 months
Pipeline Phase Distribution
Share of global pipeline by clinical phase
Active Trials by Therapeutic Area
Top therapeutic areas by active trial count
1🧬 Oncology12,400 active trials · 3,200 assets in dev
12.4K
2🧬 Neurology5,800 active trials · 1,420 assets in dev
5.8K
3🧬 Immunology4,900 active trials · 1,180 assets in dev
4.9K
4🧬 Cardio-Metabolic4,200 active trials · 980 assets in dev
4.2K
5🧬 Rare Disease3,600 active trials · 2,100 assets in dev
3.6K
6🧬 Infectious Disease2,800 active trials · 720 assets in dev
2.8K
New Trials Over Time
Daily new trials registered — last 30 days
API Platform
Life sciences intelligence at API speed
Four endpoints for every R&D workflow — structured JSON in milliseconds.
API Endpoints
Four R&D patterns
Asset & Pipeline APIReal-time pipeline, MoA, indication, stageREST
Trials API480K trials with PI, site, status, milestonesTrials
KOL & Investigator API320K PIs · influence, publications, trialsPeople
Catalyst Webhook APIFDA, readouts, congress, AdCom alertsStream
JSON Response — GET /v1/asset/MXY-2240
{
"asset_id": "MXY-2240",
"sponsor": "Acme Biotherapeutics",
"mechanism": "Anti-PD-1 monoclonal antibody",
"indication": "NSCLC · 1L · TPS ≥50%",
"phase": "Phase 3",
"fda_designations": [
"Breakthrough Therapy",
"Fast Track"
],
"estimated_readout": "2026-Q3",
"composition_patent_expiry": "2034-08-12",
"active_sites": 142,
"competitive_score": 87
}
Why Life Sciences Teams Choose MXY
The R&D data advantage
Most Complete Asset Graph
84K+ assets, 480K trials, and 320K investigators — unified across mechanism, indication, IP, and regulatory.
Catalyst-Driven Webhooks
FDA filings, readout dates, AdCom announcements, and congress abstracts streamed as webhooks — never miss a competitor catalyst.
Veeva-Ready API & Exports
Native Veeva CRM, Salesforce Health Cloud connectors. CSV / JSON / Parquet exports to S3, Snowflake, Databricks for global commercial.
Comparison
MXY vs the alternatives
How MarketXY compares to legacy CI vendors and free databases.
| Capability | MarketXY | Legacy CI Vendor | CT.gov Free | In-house Tracker |
|---|---|---|---|---|
| Pipeline depth | ✓ Pre-clinical → marketed | ~ Phase 1+ only | ✗ | ~ Manual |
| Catalyst webhooks | ✓ Real-time | ~ Email digest | ✗ | ✗ |
| KOL influence scoring | ✓ Composite + transparent | ~ Black-box | ✗ | ~ DIY |
| FDA / EMA / PMDA tracking | ✓ All three | ~ FDA only | ✗ | ~ Partial |
| Patent landscape integration | ✓ Composition + method | ~ Patent only | ✗ | ✗ |
| REST API + Veeva | ✓ JSON · Veeva ready | ~ Legacy | ~ Limited | ✗ |
| Bulk export (1M+ rows) | ✓ S3/Snowflake | ~ CSV only | ~ Slow | — |
Case Studies
Real life sciences teams, real results
Competitive Intel
Tracking 38 GLP-1 Programs Across 22 Sponsors
A top-10 pharma's CI team used MXY's mechanism + pipeline data to monitor 38 active GLP-1 / GIP programs across 22 sponsors — surfacing 4 stealth assets that filed INDs without press releases.
38GLP-1 programs
4stealth INDs found
Clinical Ops
Picking 84 Sites for a Phase 3 NSCLC Trial
A biotech sponsor used MXY's investigator + trial-volume data to short-list 84 oncology sites for a Phase 3 NSCLC study — meeting enrollment 6 months ahead of plan.
84sites activated
6moahead of plan
BD & Licensing
Sourcing 240 Pre-Clinical Oncology Assets
A pharma BD team used MXY's pre-clinical asset feed filtered by MoA + IP status to surface 240 in-licensing candidates in oncology — closing 3 deals worth $1.4B in upfronts.
240assets surfaced
$1.4Bupfronts closed
Medical Affairs
Mapping 1,800 Cardiology KOLs by Sub-Specialty
A cardiovascular-focused biotech used MXY's KOL influence score to map 1,800 cardiology KOLs by sub-specialty — accelerating advisory board recruitment by 5×.
1,800KOLs profiled
5×AB recruit speed
FAQ
Common questions
How often is the data updated?
Pipeline and trial registry data refreshes nightly. FDA filings and approvals stream within 24 hours. Publications and congress abstracts refresh weekly.
What data sources are included?
ClinicalTrials.gov, EU CTR, JP JAPIC, FDA Orange/Purple Book, FDA AdCom calendar, EMA EPAR, PubMed, ASCO/ASH/AHA/ESMO abstracts, USPTO, Google Patents, NIH RePORTER.
How do you score KOLs?
Composite score across publications (weighted by journal IF), trial volume (PI vs sub-I), congress invitations, NIH grant history, society leadership, and citation network centrality.
What export formats are available?
CSV, JSON, Parquet, and SQL on all plans. Enterprise adds direct S3 delivery, Snowflake share, and Databricks sharing for global commercial teams.
Do you have CRM integrations?
Yes. Native connectors for Veeva CRM, Salesforce Health Cloud, and IQVIA OneKey replacement — plus REST API for any custom system.
Can I monitor competitor catalysts continuously?
Yes. Set webhooks for trial milestone changes, FDA filing updates, AdCom announcements, congress abstract releases, or any custom catalyst trigger.
Start tracking your pipeline universe today
1 month free · No credit card required · GxP-friendly · Cancel anytime